Work

Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.4519

Authors: Yago Nieto, Shi-Ming Tu, Matthew T. Campbell, Roland Bassett, Nizar M. Tannir, John Francis Ward, Wayne Lewis Hofstetter, Roy B. Jones, Borje Andersson, Alison M Gulbis, Celina Ledesma, Melissa Timmons, Michelle Trapp, Richard E. Champlin, Lance C. Pagliaro

Institutions: The University of Texas MD Anderson Cancer Center, Mayo Clinic

Language: English

Topic: Testicular diseases and treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890134331

Cites:

Cited by: 5

Related to: 10